Industrialization of Highly Intensified Connected/Continuous Biomanufacturing Platform (HiCB) to Address Patient and Business Needs-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

In The News

25 Nov, 2022

- Integrate HiCB and novel facility design to provide flexibility, speed, high quality at low cost

- Platform designed to simplified PD while minimizing tech transfer, scale up and manufacturing risks

- Showcase implementation strategy and plan

back